<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1306">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05144152</url>
  </required_header>
  <id_info>
    <org_study_id>2021.558</org_study_id>
    <nct_id>NCT05144152</nct_id>
  </id_info>
  <brief_title>Diagnostic Accuracy of M3 in Predicting Colorectal Advanced Adenoma Recurrence (M3-AA)</brief_title>
  <acronym>M3-AA</acronym>
  <official_title>A Prospective Study to Assess the Diagnostic Accuracy of a Panel of Bacterial Gene Markers (M3) in Predicting Colorectal Advanced Adenoma Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to evaluate the diagnostic accuracy of FIT and the novel panel of four&#xD;
      bacterial gene markers collectively named as M3, to detect recurrent advanced adenomas in&#xD;
      patients with history of colonic adenomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal cancer (CRC) is the most common cancer in Hong Kong with more than 5,600 new cases&#xD;
      annually. There is prevailing evidence of increasing trend of young onset CRC globally. Early&#xD;
      detection and endoscopic resection of pre-malignant colonic adenomas has shown to reduce&#xD;
      CRC-related mortality.&#xD;
&#xD;
      After the index colonoscopy, a surveillance colonoscopy will be required at regular&#xD;
      intervals, depending on the number, size and histology of colonic polyps. Studies have&#xD;
      reported the use of faecal immunochemical test (FIT) to reduce the burden on surveillance&#xD;
      endoscopy service. However, approximately 30-40% of interval CRC and 40-70% of advanced&#xD;
      adenomas (AA) could be missed by this strategy. The major limitation of this widely used&#xD;
      non-invasive stool test is its unsatisfactory sensitivities for CRC (79%) and AA (40%). The&#xD;
      sensitivity for non-advanced adenomas is even lower than 10%. A large proportion of advanced&#xD;
      and non-advanced adenomas will be missed by FIT alone. Therefore, identification of&#xD;
      alternative non-invasive test with better sensitivity to detect colonic adenomas is&#xD;
      warranted.&#xD;
&#xD;
      Multitarget stool DNA test and faecal microbial DNA markers appear to be the most promising&#xD;
      stool-based diagnostic biomarkers for screening CRC. Several bacterial gene markers have been&#xD;
      identified by metagenome sequencing and reported to be associated with CRC, including&#xD;
      Fusobacterium nucleatum (Fn), Clostridium hathewayi (Ch) and Bacteroides clarus (Bc).&#xD;
      However, these molecular markers had low accuracy in distinguishing adenomas from normal&#xD;
      tissue. Recently, a new Lachnoclostridium gene marker (labelled as 'm3') has been shown to&#xD;
      have high diagnostic yield for the detection of colorectal adenomas. In a case-control study&#xD;
      of 1012 subjects, a linear increasing trend of m3 level was observed from fecal samples of&#xD;
      healthy subjects to those with adenomas and cancers. The overall sensitivity of m3 was&#xD;
      significantly higher than FIT in detecting all adenomas (48% vs 9.3%), AA (50.8% vs 16.1%)&#xD;
      and non-advanced adenomas (44.2% vs 0%). The diagnostic accuracy of m3 could be further&#xD;
      enhanced by combining with a panel of fecal microbial markers composing of Fusobacterium&#xD;
      nucleatum (Fn), Bacteroides clarus (Bc), Clostridium hathewayi (Ch) for CRC (82.3%) and&#xD;
      adenomas (64.2%). The combination of these 4 bacterial gene markers (known as M3) has&#xD;
      recently been proven to be useful in detecting adenoma recurrence after polypectomy in a&#xD;
      retrospective study [patent filed; to be published]. The hypothesis is that it would be&#xD;
      effective in the detection of recurrent advanced adenomas.&#xD;
&#xD;
      This prospective cohort study aims to evaluate the diagnostic accuracy of FIT and the novel&#xD;
      panel of four bacterial gene markers (Fn, m3, Ch and Bc) collectively named as M3, to detect&#xD;
      recurrent advanced adenomas in patients with history of colonic adenomas.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">June 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of the panel of bacterial gene markers (M3) or FIT in detection of recurrent colonic advanced adenomas</measure>
    <time_frame>3 years</time_frame>
    <description>The proportion of subjects with true positive results of either M3 or FIT among those with one of more advanced adenomas detected during the surveillance colonoscopy examination at year 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity for advanced adenomas (index)</measure>
    <time_frame>1 month</time_frame>
    <description>The proportion of subjects with true positive results of either M3 or FIT among those with one of more advanced adenomas detected at the index colonoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity for non-advanced adenomas (index and year 3)</measure>
    <time_frame>3 years</time_frame>
    <description>The proportion of subjects with true positive results of either M3 or FIT among those with one of more non-advanced adenomas detected at the index colonoscopy and year 3 colonoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity for all adenomas (index and year 3)</measure>
    <time_frame>3 years</time_frame>
    <description>The proportion of subjects with true positive results of either M3 or FIT among those with all adenomas detected at the index colonoscopy and year 3 colonoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity (index and year 3)</measure>
    <time_frame>3 years</time_frame>
    <description>The proportion of true negative results of M3/FIT among those with no adenoma detected in colonoscopy) (index and year 3)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1667</enrollment>
  <condition>Colorectal Adenoma</condition>
  <condition>Advanced Adenoma</condition>
  <condition>Colorectal Polyp</condition>
  <arm_group>
    <arm_group_label>Average risk CRC screening group</arm_group_label>
    <description>Subjects with average risk of CRC require elective colonoscopy for colorectal cancer screening or polyp surveillance, or investigation of symptoms</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>M3</intervention_name>
    <description>A panel of four bacterial gene markers (Fn, m3, Ch and Bc)</description>
    <arm_group_label>Average risk CRC screening group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FIT</intervention_name>
    <description>faecal immunochemical test</description>
    <arm_group_label>Average risk CRC screening group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subeject with average risk of colorectal adenoma who require elective colonoscopy for&#xD;
        colorectal cancer screening or polyp surveillance, or investigation of symptoms.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sujects require elective colonoscopy for colorectal cancer screening or polyp&#xD;
             surveillance, or investigation of symptoms (e.g. anemia, change of bowel habit,&#xD;
             abdominal pain, past gastrointestinal bleeding);&#xD;
&#xD;
          -  Aged ≥18 years old;&#xD;
&#xD;
          -  Written informed consent obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absolute contraindications to colonoscopy (e.g. perforation, intestinal obstruction,&#xD;
             unstable cardiopulmonary status);&#xD;
&#xD;
          -  Contraindication or conditions precluding polyp resection (e.g. active&#xD;
             gastrointestinal bleeding, significant bleeding tendency defined as platelet &lt;50 ×&#xD;
             109/L or INR &gt;2, uninterrupted anticoagulation or dual antiplatelets);&#xD;
&#xD;
          -  Previous colonic resection;&#xD;
&#xD;
          -  Known colorectal cancer or adenoma for staged procedure;&#xD;
&#xD;
          -  Personal history of colorectal cancer;&#xD;
&#xD;
          -  Personal history of polyposis syndrome;&#xD;
&#xD;
          -  Personal history of inflammatory bowel disease;&#xD;
&#xD;
          -  Known pregnancy or lactation;&#xD;
&#xD;
          -  Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4&#xD;
             or above);&#xD;
&#xD;
          -  Refusal to undergo next surveillance colonoscopy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Min Dai</last_name>
    <phone>+85266857079</phone>
    <email>mindai@link.cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Connie Seto</last_name>
    <phone>+85267028711</phone>
    <email>milkchan882@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <state>New Territories</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <reference>
    <citation>Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, Tang L, Zhao H, Stenvang J, Li Y, Wang X, Xu X, Chen N, Wu WK, Al-Aama J, Nielsen HJ, Kiilerich P, Jensen BA, Yau TO, Lan Z, Jia H, Li J, Xiao L, Lam TY, Ng SC, Cheng AS, Wong VW, Chan FK, Xu X, Yang H, Madsen L, Datz C, Tilg H, Wang J, Brünner N, Kristiansen K, Arumugam M, Sung JJ, Wang J. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017 Jan;66(1):70-78. doi: 10.1136/gutjnl-2015-309800. Epub 2015 Sep 25.</citation>
    <PMID>26408641</PMID>
  </reference>
  <reference>
    <citation>Liang JQ, Wong SH, Szeto CH, Chu ES, Lau HC, Chen Y, Fang J, Yu J, Sung JJ. Fecal microbial DNA markers serve for screening colorectal neoplasm in asymptomatic subjects. J Gastroenterol Hepatol. 2021 Apr;36(4):1035-1043. doi: 10.1111/jgh.15171. Epub 2020 Jul 15.</citation>
    <PMID>32633422</PMID>
  </reference>
  <reference>
    <citation>Liang Q, Chiu J, Chen Y, Huang Y, Higashimori A, Fang J, Brim H, Ashktorab H, Ng SC, Ng SSM, Zheng S, Chan FKL, Sung JJY, Yu J. Fecal Bacteria Act as Novel Biomarkers for Noninvasive Diagnosis of Colorectal Cancer. Clin Cancer Res. 2017 Apr 15;23(8):2061-2070. doi: 10.1158/1078-0432.CCR-16-1599. Epub 2016 Oct 3.</citation>
    <PMID>27697996</PMID>
  </reference>
  <reference>
    <citation>Wong SH, Kwong TNY, Chow TC, Luk AKC, Dai RZW, Nakatsu G, Lam TYT, Zhang L, Wu JCY, Chan FKL, Ng SSM, Wong MCS, Ng SC, Wu WKK, Yu J, Sung JJY. Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia. Gut. 2017 Aug;66(8):1441-1448. doi: 10.1136/gutjnl-2016-312766. Epub 2016 Oct 24.</citation>
    <PMID>27797940</PMID>
  </reference>
  <reference>
    <citation>Flanagan L, Schmid J, Ebert M, Soucek P, Kunicka T, Liska V, Bruha J, Neary P, Dezeeuw N, Tommasino M, Jenab M, Prehn JH, Hughes DJ. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis. 2014 Aug;33(8):1381-90. doi: 10.1007/s10096-014-2081-3. Epub 2014 Mar 6.</citation>
    <PMID>24599709</PMID>
  </reference>
  <reference>
    <citation>Amitay EL, Werner S, Vital M, Pieper DH, Höfler D, Gierse IJ, Butt J, Balavarca Y, Cuk K, Brenner H. Fusobacterium and colorectal cancer: causal factor or passenger? Results from a large colorectal cancer screening study. Carcinogenesis. 2017 Aug 1;38(8):781-788. doi: 10.1093/carcin/bgx053.</citation>
    <PMID>28582482</PMID>
  </reference>
  <reference>
    <citation>Liang JQ, Li T, Nakatsu G, Chen YX, Yau TO, Chu E, Wong S, Szeto CH, Ng SC, Chan FKL, Fang JY, Sung JJY, Yu J. A novel faecal Lachnoclostridium marker for the non-invasive diagnosis of colorectal adenoma and cancer. Gut. 2020 Jul;69(7):1248-1257. doi: 10.1136/gutjnl-2019-318532. Epub 2019 Nov 27.</citation>
    <PMID>31776231</PMID>
  </reference>
  <reference>
    <citation>Heitman SJ, Ronksley PE, Hilsden RJ, Manns BJ, Rostom A, Hemmelgarn BR. Prevalence of adenomas and colorectal cancer in average risk individuals: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009 Dec;7(12):1272-8. doi: 10.1016/j.cgh.2009.05.032. Epub 2009 Jun 10. Review.</citation>
    <PMID>19523536</PMID>
  </reference>
  <reference>
    <citation>Yamaji Y, Mitsushima T, Ikuma H, Watabe H, Okamoto M, Kawabe T, Wada R, Doi H, Omata M. Incidence and recurrence rates of colorectal adenomas estimated by annually repeated colonoscopies on asymptomatic Japanese. Gut. 2004 Apr;53(4):568-72.</citation>
    <PMID>15016753</PMID>
  </reference>
  <reference>
    <citation>Robertson DJ, Lee JK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Rex DK. Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017 Apr;152(5):1217-1237.e3. doi: 10.1053/j.gastro.2016.08.053. Epub 2016 Oct 19. Review.</citation>
    <PMID>27769517</PMID>
  </reference>
  <reference>
    <citation>Hassan C, Antonelli G, Dumonceau JM, Regula J, Bretthauer M, Chaussade S, Dekker E, Ferlitsch M, Gimeno-Garcia A, Jover R, Kalager M, Pellisé M, Pox C, Ricciardiello L, Rutter M, Helsingen LM, Bleijenberg A, Senore C, van Hooft JE, Dinis-Ribeiro M, Quintero E. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2020. Endoscopy. 2020 Aug;52(8):687-700. doi: 10.1055/a-1185-3109. Epub 2020 Jun 22.</citation>
    <PMID>32572858</PMID>
  </reference>
  <reference>
    <citation>Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014 Feb 4;160(3):171. doi: 10.7326/M13-1484. Review.</citation>
    <PMID>24658694</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 21, 2021</study_first_submitted>
  <study_first_submitted_qc>November 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Louis Ho Shing Lau</investigator_full_name>
    <investigator_title>Resident Specialist</investigator_title>
  </responsible_party>
  <keyword>FIT</keyword>
  <keyword>Bacterial marker</keyword>
  <keyword>Colonoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

